Related Experiment Video
Updated: Mar 31, 2026

Microscopic Electric Rotary Grinding of Plaques Combined with Graft Repair in the Management of Peyronie's Disease
Published on: March 15, 2024
Cardiovascular Disease Prevention in Men with Vascular Erectile Dysfunction: The View of the Preventive Cardiologist
Nishant P Shah1, Miguel Cainzos-Achirica2, David I Feldman1
1Ciccarone Center for the Prevention of Heart Disease, Department of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Md.
Insights
Vascular erectile dysfunction signals higher cardiovascular risk. This review proposes integrating erectile dysfunction evaluation with personalized tools like coronary artery calcium scoring for better cardiovascular risk assessment and management.
Area of Science:
- Cardiology
- Urology
- Preventive Medicine
Background:
- Vascular erectile dysfunction (VED) is a significant indicator of underlying cardiovascular disease (CVD).
- Current cardiovascular risk assessment guidelines lack specific recommendations for evaluating VED.
- There is a growing consensus among experts for more defined guidance on VED assessment in cardiovascular risk stratification.
Purpose of the Study:
- To provide a preventive cardiologist's perspective on the role of VED evaluation in cardiovascular risk assessment.
- To discuss limitations of existing risk scores and the utility of personalized prognostic tools for men with VED.
- To propose an integrated approach for cardiovascular risk stratification and management in patients with VED.
Main Methods:
- Review of current literature and guidelines regarding VED and cardiovascular risk.
- Analysis of the interplay between VED assessment and personalized prognostic tools (e.g., coronary artery calcium score).
- Development of a clinical decision-making algorithm for healthcare providers.
Main Results:
- Existing risk scores have limitations in fully capturing cardiovascular risk in men with VED.
- Personalized prognostic tools, such as coronary artery calcium scoring, offer valuable insights beyond traditional risk factors.
- Stress testing is considered a primary tool, with others as second-line options for risk stratification in VED patients.
Conclusions:
- Integrating VED assessment into cardiovascular risk stratification is crucial.
- Personalized prognostic tools can enhance the accuracy of risk assessment and guide management strategies for men with VED.
- A collaborative approach involving primary care, urology, and cardiology is recommended for optimal patient care.
Abstract:
Vascular erectile dysfunction is a powerful marker of increased cardiovascular risk. However, current guidelines lack specific recommendations on the role that the evaluation of vascular erectile dysfunction should play in cardiovascular risk assessment, as well on the risk stratification strategy that men with vascular erectile dysfunction should undergo. In the last 3 years, erectile dysfunction experts have made a call for more specific guidance and have proposed the selective use of several prognostic tests for further cardiovascular risk assessment in these patients. Among them, stress testing has been prioritized, whereas other tests are considered second-line tools. In this review, we provide additional perspective from the viewpoint of the preventive cardiologist. We discuss the limitations of current risk scores and the potential interplay between erectile dysfunction assessment and the use of personalized prognostic tools, such as the coronary artery calcium score, in the cardiovascular risk stratification and management of men with vascular erectile dysfunction. Finally, we present an algorithm for primary care physicians, urologists, and cardiologists to aid clinical decision-making.
More Related Videos
Related Concept Videos
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
Coronary Artery Disease IV: Preventive Measures
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Antihypertensive Drugs: Vasodilators

